Four details:
1. The study is implanting MagnetOs Putty on one side of the spine and autograft — the control material — on the other side.
2. Thirty patients will undergo a two-level instrumented posterolateral fusion.
3. The primary endpoint is the rate of posterolateral lumbar/thoracolumbar fusion, which is evaluated at 12 months.
4. MagnetOs Putty has a surface area that promotes bone growth throughout the graft for more predictable fusions, the company said in an April 13 news release.
Click here for more details on the study.
